Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 2:27 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 269 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: methylphenidate HCl Clear all
Completed Early Phase 1 Interventional Accepts healthy volunteers

Behavioral Effects of Drugs: Inpatient (35)

NCT03519022
View directory record Official record
Conditions
Cocaine Use Disorder
Interventions
Cocaine, Placebo oral capsule, Methylphenidate
Drug
Lead sponsor
Craig Rush
Other
Eligibility
18 Years to 55 Years
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jun 25, 2019 · Synced Oct 17, 2026, 2:27 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Impulsivity and Stimulant Administration

NCT01978431
View directory record Official record
Conditions
Cocaine Dependence, Impulsivity
Interventions
cocaine hydrochloride, methylphenidate
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 50 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 16, 2023 · Synced Oct 17, 2026, 2:27 PM EDT
Completed No phase listed Observational

Safety Study of Atomoxetine and Cerebrovascular Outcomes

NCT00634439
View directory record Official record
Conditions
Cerebrovascular Accident, Transient Ischemic Attack, ADHD
Interventions
atomoxetine, Stimulants, No intervention (general population)
Drug · Other
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
72,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 15, 2009 · Synced Oct 17, 2026, 2:27 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Methylphenidate for the Treatment of Epilepsy-related Cognitive Deficits

NCT04419272
View directory record Official record
Conditions
Epilepsy
Interventions
Methylphenidate, Placebo
Drug · Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
226 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
4
States / cities
Miami, Florida • Boston, Massachusetts • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Oct 17, 2026, 2:27 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Methylphenidate Hydrochloride Extended Release in Adults With Childhood-onset Attention Deficit/Hyperactivity Disorder (ADHD)

NCT01259492
View directory record Official record
Conditions
Attention Deficit/Hyperactivity Disorder
Interventions
Placebo, Ritalin LA 20 mg, Ritalin LA 30 mg
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 60 Years
Enrollment
725 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
21
States / cities
Little Rock, Arkansas • Beverly Hills, California • Spring Valley, California + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2014 · Synced Oct 17, 2026, 2:27 PM EDT
Not listed Not applicable Interventional

Attention Deficit Hyperactivity Disorder (ADHD) Prediction of Treatment Response

NCT03153488
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
MRI
Radiation
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 26, 2022 · Synced Oct 17, 2026, 2:27 PM EDT
Completed Not applicable Interventional

Methylphenidate in Children and Adolescents With Pervasive Developmental Disorders

NCT00025779
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity, Autistic Disorder, Pervasive Development Disorders
Interventions
methylphenidate, guanfacine
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
5 Years to 14 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
5
States / cities
Los Angeles, California • New Haven, Connecticut • Indianapolis, Indiana + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2009 · Synced Oct 17, 2026, 2:27 PM EDT
Not listed Phase 2 Interventional

The Synergy Trial: Methylphenidate Plus a CFS-Specific Nutrient Formula as a Treatment for Chronic Fatigue Syndrome

NCT01966276
View directory record Official record
Conditions
Chronic Fatigue Syndrome (CFS), Myalgic Encephalomyelitis (ME)
Interventions
Methyl-P plus Nutrient Formula, Methyl-P plus Nutrient matched placebos
Drug
Lead sponsor
K-PAX Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 59 Years
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
4
States / cities
Stanford, California • Fort Lauderdale, Florida • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2014 · Synced Oct 17, 2026, 2:27 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Drug Interaction Study of SPD503 and Concerta Administered Alone and In Combination in Normal Healthy Volunteers

NCT00901576
View directory record Official record
Conditions
Healthy
Interventions
SPD503, Concerta, SPD503 + Concerta
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 45 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 14, 2021 · Synced Oct 17, 2026, 2:27 PM EDT
Terminated Phase 3 Interventional Results available

Effects of Methylphenidate Versus Sustained Release Methylphenidate on Cognitive Functioning

NCT00418691
View directory record Official record
Conditions
Brain Tumor
Interventions
IR Methylphenidate, Modafinil, SR Methylphenidate
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 23, 2020 · Synced Oct 17, 2026, 2:27 PM EDT
Completed Not applicable Interventional

Treatment of Youth With ADHD and Anxiety

NCT00012584
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder, Anxiety, Separation, Social Phobia, Generalized Anxiety Disorder
Interventions
methylphenidate, fluvoxamine
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
6 Years to 17 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2002
U.S. locations
5
States / cities
Los Angeles, California • Baltimore, Maryland • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2009 · Synced Oct 17, 2026, 2:27 PM EDT
Completed Phase 1 Interventional

Patient Controlled Administration of Methylphenidate for Cancer Related Fatigue - PRN Methylphenidate

NCT02361125
View directory record Official record
Conditions
Fatigue
Interventions
Methylphenidate, Fatigue Evaluations
Drug · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 4, 2022 · Synced Oct 17, 2026, 2:27 PM EDT
Completed Phase 2 Interventional

Psychostimulants for Fatigue in Prostate Cancer

NCT00138138
View directory record Official record
Conditions
Fatigue, Prostate Cancer
Interventions
Ritalin
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
40 Years to 90 Years · Male only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 10, 2007 · Synced Oct 17, 2026, 2:27 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Stimulant Medication Effects on Auditory Sensitivity in Teens With ADHD

NCT04577417
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder, Attention Deficit Disorder, Attention Deficit Disorder With Hyperactivity
Interventions
ADHD stimulants, for example, amphetamine, dexmethylphenidate, dextroamphetamine, methylphenidate
Drug
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
13 Years to 19 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Wilmington, Delaware
Source: ClinicalTrials.gov public record
Updated Dec 13, 2022 · Synced Oct 17, 2026, 2:27 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

A Double-blind Randomized, Placebo-controlled, Crossover Study of Single Doses of OROS Methylphenidate Hydrochloride (CONCERTA) and Long-acting Methylphenidate Hydrochloride (RITALIN LA) in Healthy Adults

NCT00302354
View directory record Official record
Conditions
Healthy Volunteers
Interventions
OROS methylphenidate HCl, SODAS methylphenidate HCl
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 45 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2005
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 12, 2011 · Synced Oct 17, 2026, 2:27 PM EDT
Terminated Phase 2 Interventional

Cognitive REmediation After Trauma Exposure Trial = CREATE Trial

NCT01416948
View directory record Official record
Conditions
Posttraumatic Stress Disorder, Traumatic Brain Injury
Interventions
Methylphenidate Hydrochloride 20 mg, Placebo Capsule, Galantamine 12 mg
Drug
Lead sponsor
INTRuST, Post-Traumatic Stress Disorder - Traumatic Brain Injury Clinical Consortium
Other
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
7
States / cities
San Diego, California • Boston, Massachusetts • Manchester, New Hampshire + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2013 · Synced Oct 17, 2026, 2:27 PM EDT
Not yet recruiting Phase 4 Interventional

Delayed-Release, Extended-Release Methylphenidate (Jornay PM) for Adolescents and Young Adults With Attention-Deficit/Hyperactivity Disorder and Cannabis Use Disorder

NCT07838311
View directory record Official record
Conditions
ADHD, Cannabis Use Disorder
Interventions
Delayed-release, extended-release methylphenidate, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
16 Years to 26 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 17, 2026, 2:27 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety Assessment of Potential Interactions Between IV Methamphetamine and Osmotic-Release Methylphenidate (OROS-MPH)

NCT00603434
View directory record Official record
Conditions
Methamphetamine Dependence, Methamphetamine Abuse
Interventions
OROS-MPH
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years to 45 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Oct 17, 2026, 2:27 PM EDT
Completed Phase 4 Interventional

Naturalistic Substitution of Concerta in Adult Subject With ADHD Receiving Immediate Release Methylphenidate

NCT00302406
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
methylphenidate hydrochloride, OROS methylphenidate hydrochloride (CONCERTA)
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 55 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 12, 2011 · Synced Oct 17, 2026, 2:27 PM EDT
Completed Phase 4 Interventional Results available

A Safety/Tolerability and PK Study With Azstarys® in Children With ADHD

NCT05721235
View directory record Official record
Conditions
Attention Deficit/Hyperactivity Disorder
Interventions
Serdexmethylphenidate (SDX) and dexmethylphenidate (d-MPH)
Drug
Lead sponsor
Corium, Inc.
Industry
Eligibility
4 Years to 5 Years
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
20
States / cities
Little Rock, Arkansas • Anaheim, California • Centennial, Colorado + 17 more
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Oct 17, 2026, 2:27 PM EDT
Completed Phase 3 Interventional Results available

Methylphenidate Transdermal System (MTS) in the Treatment of Adult ADHD

NCT00506285
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Methylphenidate Transdermal System (MTS), placebo patch
Drug · Other
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 65 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jan 16, 2015 · Synced Oct 17, 2026, 2:27 PM EDT
Completed Phase 4 Interventional Results available

Study of Medication Patch to Treat Children Ages 6-12 With ADHD

NCT00586157
View directory record Official record
Conditions
ADHD, Attention Deficit Hyperactivity Disorder
Interventions
Methylphenidate Transdermal System, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
6 Years to 12 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 16, 2012 · Synced Oct 17, 2026, 2:27 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Effects of Expectation on Natural and Drug -Induced Rewards

NCT01036230
View directory record Official record
Conditions
Drug Abuse
Interventions
Not listed
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 50 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 5, 2019 · Synced Oct 17, 2026, 2:27 PM EDT
Completed Phase 4 Interventional Results available

Dose Response Effects of Quillivant XR in Children With ADHD and Autism: A Pilot Study

NCT02255565
View directory record Official record
Conditions
ADHD, Autism
Interventions
Very Low Dose Quillivant XR, Low Dose Quillivant XR, Moderate Dose Quillivant XR
Drug
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
5 Years to 16 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 1, 2017 · Synced Oct 17, 2026, 2:27 PM EDT